N/A
N=155,963
Data Analysis for Drug Repurposing for Effective Alzheimer's Medicines (DREAM)- Amiloride vs Triamterene
Hypertension
Bottom Line
View on ClinicalTrials.gov: NCT05125237 ↗Enrolled (actual)
155,963
Serious AEs
—
Results posted
Nov 2025
Primary outcome: Primary: Time to Dementia Onset — 12.6; 14.8; 20.9; 21.5 Incidence rate per 1000 person year
Study Design & Population
- Study type
- Observational
- Phase
- N/A
- Interventions
- Amiloride (Drug); Triamterene (Drug)
- Age
- Older Adult · 65+ yrs
- Sex
- All
- Sponsor
- Brigham and Women's Hospital
- Primary completion
- Jul 2023
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Time to Dementia Onset |
12.6; 14.8; 20.9; 21.5; 12.2; 17.4 | — |
Summary
This study aims to evaluate the comparative risk of dementia/Alzheimer's disease onset between patients treated with medications that target specific metabolic pathways and patients treated with alternative medications for the same indication.
Eligibility Criteria
Please see https://docs.google.com/spreadsheets/d/1IdoLUI5-bz\_1D\_0IflZovJO9e1\_3kFLc\_JLEFM030No/edit?usp=sharing or Appendix A for full code and algorithm definitions.
Medicare timeframe: 2008 to 2018 (end of data availability).
Inclusion Criteria
- 1. Aged > 65 years on the index date
- 2. Enrollment in Medicare Part A, B, and D with no HMO coverage for 365 days prior to and including cohort entry date
- 3. At least two claims with hypertension diagnosis recorded in 365 days prior to cohort entry date
Exclusion Criteria
- 1. Prior history of dementia measured anytime prior to cohort entry date
- 2. Prior use of amiloride or triamterene any time prior to cohort entry date
Data sourced from ClinicalTrials.gov (NCT05125237). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.